$188.81
3.43[1.85%]
At close: May 17
$188.81
0[0.00%]
After Hours: 4:11PM EDT
Insulet
(NASDAQ:PODD)Insulet Stock (NASDAQ:PODD), Analyst Ratings, Price Targets, Predictions
Insulet Corp has a consensus price target of $259.16, established from looking at the 75 latest analyst ratings. The last 3 analyst ratings were released from Barclays, Canaccord Genuity, and Raymond James on May 13, 2024, May 10, 2024, and May 10, 2024. With an average price target of $215.67 between Barclays, Canaccord Genuity, and Raymond James, there's an implied 14.22% upside for Insulet Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Canaccord Genuity
Raymond James
Jefferies
Wolfe Research
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Insulet
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2024 | Buy Now | 5.93% | Barclays | Matt Miksic | $213 → $200 | Maintains | Equal-Weight | Get Alert |
| 05/10/2024 | Buy Now | 23.93% | Canaccord Genuity | Kyle Rose | $226 → $234 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 12.81% | Raymond James | Jayson Bedford | $218 → $213 | Maintains | Outperform | Get Alert |
| 05/10/2024 | Buy Now | 37.7% | Jefferies | Matthew Taylor | $255 → $260 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 5.93% | Wolfe Research | Mike Polark | → $200 | Upgrade | Peer Perform → Outperform | Get Alert |
| 02/26/2024 | Buy Now | 12.81% | Barclays | Matt Miksic | $214 → $213 | Maintains | Equal-Weight | Get Alert |
| 02/23/2024 | Buy Now | 21.82% | Piper Sandler | Matt O'Brien | $250 → $230 | Maintains | Overweight | Get Alert |
| 02/23/2024 | Buy Now | 19.17% | JP Morgan | Robbie Marcus | $190 → $225 | Maintains | Overweight | Get Alert |
| 02/05/2024 | Buy Now | 10.16% | Stifel | Mathew Blackman | $163 → $208 | Maintains | Hold | Get Alert |
| 12/21/2023 | Buy Now | 26.05% | Baird | Jeff Johnson | $180 → $238 | Upgrade | Neutral → Outperform | Get Alert |
| 12/04/2023 | Buy Now | 23.93% | Morgan Stanley | Patrick Wood | $185 → $234 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/03/2023 | Buy Now | 32.41% | Piper Sandler | Matt O'Brien | $325 → $250 | Maintains | Overweight | Get Alert |
| 10/17/2023 | Buy Now | -14.2% | JP Morgan | Robbie Marcus | $325 → $162 | Maintains | Overweight | Get Alert |
| 10/16/2023 | Buy Now | -2.55% | Leerink Partners | Mike Kratky | → $184 | Initiates | → Outperform | Get Alert |
| 10/02/2023 | Buy Now | 27.11% | Jefferies | Matthew Taylor | $260 → $240 | Upgrade | Hold → Buy | Get Alert |
| 09/29/2023 | Buy Now | -2.02% | Morgan Stanley | Patrick Wood | $208 → $185 | Maintains | Equal-Weight | Get Alert |
| 09/15/2023 | Buy Now | 20.76% | Raymond James | Jayson Bedford | $299 → $228 | Maintains | Outperform | Get Alert |
| 09/06/2023 | Buy Now | 13.87% | UBS | Matthew Taylor | $270 → $215 | Maintains | Neutral | Get Alert |
| 08/24/2023 | Buy Now | 56.24% | B of A Securities | Travis Steed | $365 → $295 | Maintains | Buy | Get Alert |
| 08/24/2023 | Buy Now | 10.16% | Morgan Stanley | Patrick Wood | $343 → $208 | Maintains | Equal-Weight | Get Alert |
| 08/21/2023 | Buy Now | 40.35% | Citigroup | Joanne Wuensch | $273 → $265 | Upgrade | Neutral → Buy | Get Alert |
| 08/21/2023 | Buy Now | 15.99% | Baird | Jeff Johnson | $320 → $219 | Downgrade | Outperform → Neutral | Get Alert |
| 08/10/2023 | Buy Now | 36.12% | Barclays | Matt Miksic | $329 → $257 | Maintains | Equal-Weight | Get Alert |
| 08/09/2023 | Buy Now | 58.89% | TD Cowen | Josh Jennings | $350 → $300 | Maintains | Outperform | Get Alert |
| 08/09/2023 | Buy Now | 72.13% | JP Morgan | Robbie Marcus | $365 → $325 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 44.59% | Citigroup | Joanne Wuensch | $319 → $273 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | 74.78% | Wells Fargo | Lawrence Biegelsen | $375 → $300 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 58.36% | Raymond James | Jayson Bedford | $350 → $299 | Maintains | Outperform | Get Alert |
| 07/11/2023 | Buy Now | 68.95% | Citigroup | Joanne Wuensch | $330 → $319 | Maintains | Neutral | Get Alert |
| 05/30/2023 | Buy Now | 81.66% | Morgan Stanley | Patrick Wood | → $343 | Assumes | → Equal-Weight | Get Alert |
FAQ
What is the target price for Insulet (PODD)?
The latest price target for Insulet (NASDAQ: PODD) was reported by Barclays on May 13, 2024. The analyst firm set a price target for $200.00 expecting PODD to rise to within 12 months (a possible 5.93% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Insulet (PODD)?
The latest analyst rating for Insulet (NASDAQ: PODD) was provided by Barclays, and Insulet maintained their equal-weight rating.
When was the last upgrade for Insulet (PODD)?
The last upgrade for Insulet Corp happened on May 7, 2024 when Wolfe Research raised their price target to $200. Wolfe Research previously had a peer perform for Insulet Corp.
When was the last downgrade for Insulet (PODD)?
The last downgrade for Insulet Corp happened on August 21, 2023 when Baird changed their price target from $320 to $219 for Insulet Corp.
When is the next analyst rating going to be posted or updated for Insulet (PODD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Insulet, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Insulet was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
Is the Analyst Rating Insulet (PODD) correct?
While ratings are subjective and will change, the latest Insulet (PODD) rating was a maintained with a price target of $213.00 to $200.00. The current price Insulet (PODD) is trading at is $188.81, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.